Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl亚型特异性产品:Bcr-Abl Isoform Comparison
共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
DPH

DPH 是一种有效的、细胞渗透性的 c-Abl 激活剂,在酶和细胞活动中均能有效刺激 c-Abl 的活化。

484049-04-9
Activator
99.38%
DPH

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础